Zacks Investment Research on MSN
BioMarin Beats on Q3 Earnings, Seeks to Divest Hemophilia Gene Therapy
BioMarin Pharmaceutical BMRN reported third-quarter 2025 adjusted earnings per share (EPS) of 12 cents against the Zacks ...
Citizens JMP upgraded Spruce Biosciences (SPRB) to Outperform from Market Perform with a $254 price target The firm cites the company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback